April 29 Quick Takes: Faron, Orchard

Faron's Traumakine fails Japanese Phase III for ARDS
Faron Pharmaceuticals Oy (LSE:FARN) said partner Maruishi Pharmaceutical Co. Ltd. (Osaka, Japan) reported that Traumakine missed the primary endpoint in a Japanese Phase III trial to treat acute respiratory distress syndrome. As seen in the previous European Phase III INTEREST trial, corticosteroid use diminished the treatment benefit of Traumakine, Faron said (see "Faron's Traumakine Misses in Phase III for Acute Respiratory Distress Syndrome")...